Alivio Therapeutics has collaborated with Purdue Pharma to advance its ALV-107 product into clinical development as a non-opioid therapy for potential treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
The deal provides Purdue Pharma with an option to partner on certain additional candidates that are based on Alivio’s inflammation-targeting technology.
Go deeper with GlobalData
Alivio’s technology allows therapeutics, including small molecules, biologics and nucleic acids, to exclusively act at sites of inflammation, without affecting healthy tissue.
The company is carrying out an in-house assessment of the technique in different inflammatory diseases such as IC/BPS, pouchitis and inflammatory bowel disease (IBD).
When tested in preclinical models, ALV-107 was found to have relieved pain at all study time points after therapy.
The partners now intend to investigate the product’s safety and efficacy in a clinical development programme.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPurdue Pharma president and CEO Craig Landau said: “This collaboration with Alivio is an important milestone in our continued pursuit of non-opioid treatments for pain and represents yet another step to further diversify our portfolio.
“We are impressed with Alivio’s innovative platform technology as we focus on addressing patient needs – especially in areas where there are few efficacious treatment options.”
Under the terms of the alliance, Purdue will pay $14.75m in upfront and near-term licence exercise payments to Alivio. Alivio will also receive royalties on product sales and more than $260m in research and development milestones.
In addition, Purdue holds an option to invest in Alivio’s next equity financing.
Alivio Therapeutics co-founder Eric Elenko said: “Alivio’s non-opioid approach could provide a novel treatment option for a disease where there is a tremendous unmet need.
“The Alivio platform technology is designed to address a range of inflammatory conditions, and we are rapidly progressing its potential application across pouchitis and inflammatory bowel disease as part of our internal R&D.”
The deal comes at a time when Purdue Pharma is being accused of aggressive and misleading marketing of its opioid medication OxyContin.
Massachusetts attorney general’s office filed a lawsuit claiming that eight members of the family that owns Purdue Pharma have fuelled the opioid crisis in the country via false marketing of the drug.
